

Table SI. Pathological characteristics of patients with pulmonary adenocarcinoma who received complete resection.

Characteristic	AYAs (n=61)	Older adults (n=220)	P-value
Sex, n (%)			0.092
Male	25 (41.0)	117 (53.2)	
Female	36 (59.0)	103 (46.8)	
Main microscopic pattern, n (%)			
Lepidic	14 (23.0)	40 (18.2)	0.403
Acinar	28 (45.9)	87 (39.5)	0.372
Papillary	3 (4.9)	24 (10.9)	0.160
Solid	15 (24.6)	52 (23.6)	0.877
Micropapillary	1 (1.6)	4 (1.8)	NA
Micropapillary $\geq 5\%$	7 (11.5)	13 (5.9)	0.224
T stage, n (%)			0.461
T1	36 (59.0)	109 (49.5)	
T2	21 (34.4)	83 (37.7)	
T3	2 (3.3)	13 (5.9)	
T4	2 (3.3)	15 (6.8)	
Nstage, n (%)			0.260
N0	36(59.0)	143 (65.0)	
N1	3(4.9)	19 (8.6)	
N2	22(36.1)	58 (26.4)	
TNM stage, n (%)			0.598
I	33(54.1)	119 (54.1)	
II	4 (6.6)	26 (11.8)	
III	22 (36.1)	66 (30.0)	
IV	2 (3.3)	9 (4.1)	

All categorical variables were compared using χ^2 or Fisher's exact test, as appropriate. AYAs, Adolescents and young adults; NA, not available; TNM, Tumor-Node-Metastasis.

Table SII. Grade 3-4 TRAEs following first-line systemic treatment.^a

A, Anti-EGFR for 64 AYAs and 164 older adults			
Grade 3-4 TRAEs	AYAs, n (%)	Older adults, n (%)	P-value
Total	21 (32.8)	45 (27.4)	0.421
Elevated aminotransferase	7 (10.9)	12 (7.3)	0.374
Renal dysfunction	1 (1.6)	3 (1.8)	N/A
Paronychia	1 (1.6)	0 (0.0)	0.281
Skin rash	4 (6.3)	9 (5.5)	0.924
Hypertension	0 (0.0)	1 (0.6)	N/A
Diarrhea	4 (6.3)	8 (4.9)	0.931
Nausea and vomiting	0 (0.0)	3 (1.8)	0.561
Neutropenia	2 (3.1)	7 (4.3)	0.984
Anemia	2 (3.1)	4 (2.4)	0.674
B, Anti-ALK/ROS1 for 13 AYAs and 29 older adults			
Grade 3-4 TRAEs	AYAs, n (%)	Older adults, n (%)	P-value
Total	3 (23.1)	8 (27.6)	0.942
Neutropenia	1 (7.7)	2 (6.9)	N/A
Diarrhea	1 (7.7)	1 (3.4)	0.528
Elevated aminotransferase	1 (7.7)	2 (6.9)	N/A
Stomatitis	0 (0.0)	1 (3.4)	N/A
Anemia	0 (0.0)	1 (3.4)	N/A
Fatigue	0 (0.0)	1 (3.4)	N/A
C, Chemotherapy for 74 AYAs and 235 older adults			
Grade 3-4 TRAEs	AYAs, n (%)	Older adults, n (%)	P-value
Total	39 (52.7)	156 (66.4)	0.033
Neutropenia	11 (14.9)	68 (28.9)	0.016
Thrombocytopenia	4 (5.4)	14 (6.0)	0.914
Nausea and vomiting	5 (6.8)	15 (6.4)	0.875
Fatigue	3 (4.1)	11 (4.7)	0.925
Elevated aminotransferase	3 (4.1)	12 (5.1)	0.954
Anemia	7 (9.5)	31 (13.2)	0.394
Stomatitis	0 (0.0)	1 (0.4)	N/A
Dizziness	0 (0.0)	1 (0.4)	N/A
Diarrhea	1 (1.4)	5 (2.1)	N/A

Hiccups	1 (1.4)	2 (0.9)	0.561
Peripheral neuropathy	0 (0.0)	1 (0.4)	N/A
Skin rash	0 (0.0)	1 (0.4)	N/A
Renal dysfunction	1 (1.4)	8 (3.4)	0.603
Hypokalemia	1 (1.4)	1(0.4)	0.422

^aSubtypes of TRAEs per treatment type are shown for AYAs and older adults. TRAE, treatment-related adverse event; AYAs, adolescents and young adults; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, ROS proto-oncogene 1 receptor tyrosine kinase; NA, not available.

Table SIII. Metastatic pattern of AYAs and older adults with lung adenocarcinoma and epidermal growth factor receptor mutation.

Variables	AYAs (n=64)	Older adults (n=164)	P-value
Metastatic organs, n (%)			
Bone	34 (53.1)	74 (45.1)	0.277
Lung	32 (50.0)	64 (39.0)	0.131
Pleura	25 (39.1)	63 (38.4)	0.928
Liver	5 (7.8)	12 (7.3)	0.898
Brain	23 (35.9)	44 (26.8)	0.175
Adrenal gland	9 (14.1)	6 (3.7)	0.011
Others	1 (1.6)	2 (1.2)	N/A
Number of metastatic organs, n (%)			0.015
0	2 (3.1)	9 (5.5)	
1	20 (31.3)	71 (43.3)	
2	22 (34.4)	55 (33.5)	
3	17 (26.6)	27 (16.5)	
4	3 (4.7)	2 (1.2)	

AYAs, adolescents and young adults; NA, not available.